1
|
Ariaee A, Wardill HR, Wignall A, Prestidge CA, Joyce P. The Degree of Inulin Polymerization Is Important for Short-Term Amelioration of High-Fat Diet (HFD)-Induced Metabolic Dysfunction and Gut Microbiota Dysbiosis in Rats. Foods 2024; 13:1039. [PMID: 38611345 PMCID: PMC11011263 DOI: 10.3390/foods13071039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2024] [Revised: 03/19/2024] [Accepted: 03/26/2024] [Indexed: 04/14/2024] Open
Abstract
Inulin, a non-digestible polysaccharide, has gained attention for its prebiotic properties, particularly in the context of obesity, a condition increasingly understood as a systemic inflammatory state linked to gut microbiota composition. This study investigates the short-term protective effects of inulin with different degrees of polymerization (DPn) against metabolic health deterioration and gut microbiota alterations induced by a high-fat diet (HFD) in Sprague Dawley rats. Inulin treatments with an average DPn of 7, 14, and 27 were administered at 1 g/kg of bodyweight to HFD-fed rats over 21 days. Body weight, systemic glucose levels, and proinflammatory markers were measured to assess metabolic health. Gut microbiota composition was analyzed through 16S rRNA gene sequencing. The results showed that inulin27 significantly reduced total weight gain and systemic glucose levels, suggesting a DPn-specific effect on metabolic health. The study also observed shifts in gut microbial populations, with inulin7 promoting several beneficial taxa from the Bifidobacterium genera, whilst inducing a unique microbial composition compared to medium-chain (DPn 14) and long-chain inulin (DPn: 27). However, the impact of inulin on proinflammatory markers and lipid metabolism parameters was not statistically significant, possibly due to the short study duration. Inulin with a higher DPn has a more pronounced effect on mitigating HFD-induced metabolic health deterioration, whilst inulin7 is particularly effective at inducing healthy microbial shifts. These findings highlight the benefits of inulin as a dietary adjuvant in obesity management and the importance of DPn in optimizing performance.
Collapse
Affiliation(s)
- Amin Ariaee
- UniSA Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia; (A.A.); (A.W.); (C.A.P.)
| | - Hannah R. Wardill
- School of Biomedicine, The University of Adelaide, Adelaide, SA 5000, Australia;
- Supportive Oncology Research Group, Precision Cancer Medicine, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia
| | - Anthony Wignall
- UniSA Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia; (A.A.); (A.W.); (C.A.P.)
| | - Clive A. Prestidge
- UniSA Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia; (A.A.); (A.W.); (C.A.P.)
| | - Paul Joyce
- UniSA Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia; (A.A.); (A.W.); (C.A.P.)
| |
Collapse
|
2
|
Savytska M, Kyriienko D, Zaychenko G, Ostapchenko D, Falalyeyeva T, Kobyliak N. Probiotic co-supplementation with absorbent smectite for pancreatic beta-cell function in type 2 diabetes: a secondary-data analysis of a randomized double-blind controlled trials. Front Endocrinol (Lausanne) 2024; 15:1276642. [PMID: 38405158 PMCID: PMC10890794 DOI: 10.3389/fendo.2024.1276642] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2023] [Accepted: 01/18/2024] [Indexed: 02/27/2024] Open
Abstract
Introduction There is growing evidence from animal and clinical studies suggesting probiotics can positively affect type 2 diabetes (T2D). In a previous randomized clinical study, we found that administering a live multistrain probiotic and absorbent smectite once a day for eight weeks to patients with T2D could reduce chronic systemic inflammatory state, insulin resistance, waist circumference and improve the glycemic profile. However, there is a lack of evidence supporting the efficacy of probiotic co-supplementation with absorbent smectite on pancreatic β-cell function in T2D. Aim This secondary analysis aimed to assess the effectiveness of an alive multistrain probiotic co-supplementation with absorbent smectite vs placebo on β-cell function in T2D patients. Material and methods We performed a secondary analysis on a previously published randomized controlled trial (NCT04293731, NCT03614039) involving 46 patients with T2D. The main inclusion criteria were the presence of β-cell dysfunction (%B<60%) and insulin therapy alone or combined with oral anti-diabetic drugs. The primary outcome was assessing β-cell function as change C-peptide and %B. Results We observed only a tendency for improving β-cell function (44.22 ± 12.80 vs 55.69 ± 25.75; р=0.094). The effectiveness of the therapy probiotic-smectite group was confirmed by fasting glycemia decreased by 14% (p=0.019), HbA1c - 5% (p=0.007), HOMA-2 - 17% (p=0.003) and increase of insulin sensitivity by 23% (p=0.005). Analysis of the cytokine profile showed that statistical differences after treatment were in the concentration of both pro-inflammatory cytokines: IL-1β (22.83 ± 9.04 vs 19.03 ± 5.57; p=0.045) and TNF-α (31.25 ± 11.32 vs 26.23 ± 10.13; p=0.041). Conclusion Adding a live multistrain probiotic and absorbent smectite supplement slightly improved β-cell function and reduced glycemic-related parameters in patients with T2D. This suggests that adjusting the gut microbiota could be a promising treatment for diabetes and warrants further investigation through more extensive studies.
Collapse
Affiliation(s)
- Maryana Savytska
- Normal Physiology Department, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
| | | | - Ganna Zaychenko
- Pharmacology Department, Bogomolets National Medical University, Kyiv, Ukraine
| | - Danylo Ostapchenko
- Educational-Scientific Center “Institute of Biology and Medicine” Taras Shevchenko National University of Kyiv, Kyiv, Ukraine
| | - Tetyana Falalyeyeva
- Educational-Scientific Center “Institute of Biology and Medicine” Taras Shevchenko National University of Kyiv, Kyiv, Ukraine
- Medical Laboratory CSD, Kyiv, Ukraine
| | - Nazarii Kobyliak
- Medical Laboratory CSD, Kyiv, Ukraine
- Endocrinology Department, Bogomolets National Medical University, Kyiv, Ukraine
| |
Collapse
|
3
|
Jin H, Lu W, Zhang Y, Wu Y, Ding J, Orion IRCV, Liu C. Functionalized Periodic Mesoporous Silica Nanoparticles for Inhibiting the Progression of Atherosclerosis by Targeting Low-Density Lipoprotein Cholesterol. Pharmaceutics 2024; 16:74. [PMID: 38258085 PMCID: PMC10821319 DOI: 10.3390/pharmaceutics16010074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Revised: 12/27/2023] [Accepted: 12/30/2023] [Indexed: 01/24/2024] Open
Abstract
Atherosclerotic disease is a substantial global burden, and existing treatments, such as statins, are recommended to lower low-density lipoprotein cholesterol (LDL-C) levels and inhibit the progression of atherosclerosis. However, side effects, including gastrointestinal unease, potential harm to the liver, and discomfort in the muscles, might be observed. In this study, we propose a novel method using periodic mesoporous silica nanoparticles (PMS) to create heparin-modified PMS (PMS-HP) with excellent biocompatibility, enabling selective removal of LDL-C from the blood. In vitro, through the introduction of PMS-HP into the plasma of mice, we observed that, compared to PMS alone, PMS-HP could selectively adsorb LDL-C while avoiding interference with valuable components such as plasma proteins and high-density lipoprotein cholesterol (HDL-C). Notably, further investigations revealed that the adsorption of LDL-C by PMS-HP could be well-fitted to quasi-first-order (R2 = 0.993) and quasi-second-order adsorption models (R2 = 0.998). Likewise, in vivo, intravenous injection of PMS-HP enabled targeted LDL-C adsorption (6.5 ± 0.73 vs. 8.6 ± 0.76 mM, p < 0.001) without affecting other plasma constituents, contributing to reducing intravascular plaque formation (3.66% ± 1.06% vs. 1.87% ± 0.79%, p < 0.05) on the aortic wall and inhibiting vascular remodeling (27.2% ± 6.55% vs. 38.3% ± 1.99%, p < 0.05). Compared to existing lipid adsorption techniques, PMS-HP exhibited superior biocompatibility and recyclability, rendering it valuable for both in vivo and in vitro applications.
Collapse
Affiliation(s)
- Hao Jin
- Department of Cardiology, Zhongda Hospital Affiliated with Southeast University, Nanjing 210009, China; (H.J.); (Y.Z.); (Y.W.); (I.R.C.V.O.)
| | - Wenbin Lu
- Department of Cardiology, Zhongda Hospital Affiliated with Southeast University, Nanjing 210009, China; (H.J.); (Y.Z.); (Y.W.); (I.R.C.V.O.)
| | - Yahao Zhang
- Department of Cardiology, Zhongda Hospital Affiliated with Southeast University, Nanjing 210009, China; (H.J.); (Y.Z.); (Y.W.); (I.R.C.V.O.)
| | - Yong Wu
- Department of Cardiology, Zhongda Hospital Affiliated with Southeast University, Nanjing 210009, China; (H.J.); (Y.Z.); (Y.W.); (I.R.C.V.O.)
| | - Jiandong Ding
- Department of Cardiology, Zhongda Hospital Affiliated with Southeast University, Nanjing 210009, China; (H.J.); (Y.Z.); (Y.W.); (I.R.C.V.O.)
| | - I. R. Chiara Villamil Orion
- Department of Cardiology, Zhongda Hospital Affiliated with Southeast University, Nanjing 210009, China; (H.J.); (Y.Z.); (Y.W.); (I.R.C.V.O.)
| | - Cihui Liu
- Department of Biomedical Sciences, Nanjing Normal University, Nanjing 210023, China;
| |
Collapse
|
4
|
Lu W, Jin H, Ding J, Zhang Y, Wu Y. New application of a periodic mesoporous nanocrystal silicon-silica composite for hyperlipidemia. NANOSCALE ADVANCES 2023; 5:4286-4297. [PMID: 37560424 PMCID: PMC10408577 DOI: 10.1039/d3na00467h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Accepted: 07/08/2023] [Indexed: 08/11/2023]
Abstract
The integration of the properties of silicon nano crystallinity with silica mesoporosity provides a wealth of new opportunities for emerging biomedicine. Cholesterol (CHO) and triglyceride (TG) levels have always been a challenge for cardiologists in the treatment of patients with chronic coronary artery disease (CAD). For patients with hyperlipidemia, statins and other lipid-lowering drugs are currently recommended. It should be noted, however, that significant side effects have been reported in the treatments, including liver damage, muscle pain, etc. We here found that our previously produced periodic mesoporous nanocrystalline silicon-silica, meso-ncSi/SiO2 (PMS), a nanocomposite material, has the properties of lowering CHO and TG, and is associated with better safety and biocompatibility compared to existing lipid-lowering drugs. After being incubated with PMS for 2 hours, CHO and TG levels in blood were significantly lower than before. In addition, CHO and TG adsorbed on with PMS could also be extracted and released, contributing to the recovery and recycling of PMS.
Collapse
Affiliation(s)
- Wenbin Lu
- Department of Cardiology, Zhongda Hospital, Southeast University 87#, Dingjiaqiao Road Nanjing 210009 China
| | - Hao Jin
- Department of Cardiology, Zhongda Hospital, Southeast University 87#, Dingjiaqiao Road Nanjing 210009 China
| | - Jiandong Ding
- Department of Cardiology, Zhongda Hospital, Southeast University 87#, Dingjiaqiao Road Nanjing 210009 China
| | - Yahao Zhang
- Department of Cardiology, Zhongda Hospital, Southeast University 87#, Dingjiaqiao Road Nanjing 210009 China
| | - Yong Wu
- Department of Cardiology, Zhongda Hospital, Southeast University 87#, Dingjiaqiao Road Nanjing 210009 China
| |
Collapse
|
5
|
Chen J, Hanrahan JP, McGrath J, Courtney MA, Prestidge CA, Joyce P. The Anti-Obesity Effect of Porous Silica Is Dependent on Pore Nanostructure, Particle Size, and Surface Chemistry in an In Vitro Digestion Model. Pharmaceutics 2022; 14:pharmaceutics14091813. [PMID: 36145561 PMCID: PMC9502391 DOI: 10.3390/pharmaceutics14091813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Revised: 08/24/2022] [Accepted: 08/26/2022] [Indexed: 11/16/2022] Open
Abstract
The potential for porous silica to serve as an effective anti-obesity agent has received growing attention in recent years. However, neither the exact pharmacological mechanism nor the fundamental physicochemical properties of porous silica that drive its weight-lowering effect are well understood. Subsequently, in this study, an advanced in vitro digestion model capable of monitoring lipid and carbohydrate digestion was employed to elucidate the effect of porous silica supplementation on digestive enzyme activities. A suite of porous silica samples with contrasting physicochemical properties was investigated, where it was established that the inhibitory action of porous silica on digestive enzyme functionality was strongly dependent on porous nanostructure, particle size and morphology, and surface chemistry. Insights derived from this study validate the capacity of porous silica to impede the digestive processes mediated by pancreatic lipase and α-amylase within the gastrointestinal tract, while the subtle interplay between porous nanostructure and enzyme inhibition indicates that the anti-obesity effect can be optimized through strategic particle design.
Collapse
Affiliation(s)
- JingYi Chen
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide, SA 5000, Australia
| | | | - Joe McGrath
- Glantreo Limited, ERI Building Lee Road, T23 XE10 Cork, Ireland
| | | | - Clive A. Prestidge
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide, SA 5000, Australia
| | - Paul Joyce
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide, SA 5000, Australia
- Correspondence:
| |
Collapse
|
6
|
Biomaterial-Based Therapeutic Strategies for Obesity and Its Comorbidities. Pharmaceutics 2022; 14:pharmaceutics14071445. [PMID: 35890340 PMCID: PMC9320151 DOI: 10.3390/pharmaceutics14071445] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2022] [Revised: 07/02/2022] [Accepted: 07/04/2022] [Indexed: 02/01/2023] Open
Abstract
Obesity is a global public health issue that results in many health complications or comorbidities, including type 2 diabetes mellitus, cardiovascular disease, and fatty liver. Pharmacotherapy alone or combined with either lifestyle alteration or surgery represents the main modality to combat obesity and its complications. However, most anti-obesity drugs are limited by their bioavailability, target specificity, and potential toxic effects. Only a handful of drugs, including orlistat, liraglutide, and semaglutide, are currently approved for clinical obesity treatment. Thus, there is an urgent need for alternative treatment strategies. Based on the new revelation of the pathogenesis of obesity and the efforts toward the multi-disciplinary integration of materials, chemistry, biotechnology, and pharmacy, some emerging obesity treatment strategies are gradually entering the field of preclinical and clinical research. Herein, by analyzing the current situation and challenges of various new obesity treatment strategies such as small-molecule drugs, natural drugs, and biotechnology drugs, the advanced functions and prospects of biomaterials in obesity-targeted delivery, as well as their biological activities and applications in obesity treatment, are systematically summarized. Finally, based on the systematic analysis of biomaterial-based obesity therapeutic strategies, the future prospects and challenges in this field are proposed.
Collapse
|
7
|
Kiaee G, Dimitrakakis N, Sharifzadeh S, Kim HJ, Avery RK, Moghaddam KM, Haghniaz R, Yalcintas EP, Barros NRD, Karamikamkar S, Libanori A, Khademhosseini A, Khoshakhlagh P. Laponite-Based Nanomaterials for Drug Delivery. Adv Healthc Mater 2022; 11:e2102054. [PMID: 34990081 PMCID: PMC8986590 DOI: 10.1002/adhm.202102054] [Citation(s) in RCA: 34] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2021] [Revised: 11/29/2021] [Indexed: 11/09/2022]
Abstract
Laponite is a clay-based material composed of synthetic disk-shaped crystalline nanoparticles with highly ionic, large surface area. These characteristics enable the intercalation and dissolution of biomolecules in Laponite-based drug delivery systems. Furthermore, Laponite's innate physicochemical properties and architecture enable the development of tunable pH-responsive drug delivery systems. Laponite's coagulation capacity and cation exchangeability determine its exchange capabilities, drug encapsulation efficiency, and release profile. These parameters are exploited to design highly controlled and efficacious drug delivery platforms for sustained drug release. In this review, they provide an overview of how to design efficient delivery of therapeutics by leveraging the properties and specific interactions of various Laponite-polymer composites and drug moieties.
Collapse
Affiliation(s)
- Gita Kiaee
- Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, 02115, USA
| | - Nikolaos Dimitrakakis
- Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, 02115, USA
| | | | - Han-Jun Kim
- Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90024, USA
| | - Reginald K Avery
- Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, 02115, USA
| | | | - Reihaneh Haghniaz
- Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90024, USA
| | | | | | | | - Alberto Libanori
- Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA, 90095, USA
| | - Ali Khademhosseini
- Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90024, USA
| | - Parastoo Khoshakhlagh
- Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, 02115, USA
| |
Collapse
|